Evogene Ltd

-0.10 (-7.75%)
Earnings Announcements

Biomica Reports Positive Results From Pre-Clinical Studies In Its IBD Program

Published: 11/30/2021 12:26 GMT
Evogene Ltd (EVGN) - Biomica - Reported Today Positive Results From Pre-clinical Studies in Its Ibd Program.
Biomica - Expects to Begin Scale-up Development Processes of Bmc333 in 2022, in Preparation for Production of an Initial Clinical Batch.
Biomica - Bmc333 is Expected to Undergo Additional Pre-clinical Studies, Including in Collaboration With Laboratory of Prof.
R. Balfour Sartor.
Revenue is expected to be $0.17 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0.3 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.